113
Participants
Start Date
April 30, 2004
Primary Completion Date
January 31, 2009
Study Completion Date
April 30, 2009
APC8015F
APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
UCLA, Los Angeles
USC Keck School of Medicine, Los Angeles
Sutter Cancer Center, Sacramento
Kaiser Permanente Medical Group, San Diego
Sharp HealthCare, San Diego
UCSF Cancer Center, San Francisco
Helen F. Graham Cancer Center, Newark
Lombardi Cancer Center, Washington D.C.
Walter Reid Army Medical Center, Washington D.C.
Miami Cancer Center, Miami
Hematology/Oncology Associates of the Treasure Coast, Port Saint Lucie
Georgia Urology, P.A., Atlanta
Midwest Prostate & Urology Health Center, Chicago
Loyola University, Maywood
Lutheran General Cancer Center, Park Ridge
Indiana University, Indianapolis
Myron I Murdock MD LLC, Greenbelt
Dana-Farber Cancer Institute, Boston
Lahey Clinic (Department of Urology), Burlington
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Nevada Cancer Institute, Las Vegas
Hackensack University Medical Center, Hackensack
Associates in Urology, LLC, West Orange
Albany Regional Cancer Center, Albany
The Urological Institute of Northeastern New York, Albany
North Shore Hematology Oncology Associates, East Setauket
New York Medical College, Hawthorne
Beth Israel Cancer Center, New York
Clinical Cancer Center, New York
Mount Sinai School of Medicine, New York
New York University, New York
Staten Island Urological Research, Staten Island
McKay Urology, Charlotte
Duke University Medical Center, Durham
University of Cincinnati, Cincinnati
Cleveland Clinic Foundation, Cleveland
EACRI, Portland
Kaiser Permanente Medical Group, Portland
Center for Urologic Care, Bryn Mawr
Jefferson Medical College, Philadelphia
Grand Strand Urology, Myrtle Beach
Mary Crowley, Dallas
Baylor College of Medicine, Houston
University of Utah, Salt Lake City
Urology of Virginia, PC, Norfolk
Seattle Cancer Care Alliance, Seattle
Virginia Mason Medical Center, Seattle
Cancer Care Northwest, Spokane
Wenatchee Valley Medical Center, Wenatchee
University of Wisconsin, Madison, Madison
University of Wisconsin, Madison
St. Luke's Hospital Immunotherapy Program, Milwaukee
Can-Med Medical Research, Inc., Victoria
London Health Sciences Centre, London
Princess Margaret Hospital, Toronto
Sunnybrook & Women's College HSC, Toronto
Hospital Notre Dame du CHUM, Montreal
Lead Sponsor
Dendreon
INDUSTRY